Drug Information

Drug General Information
Drug ID
D05TNK
Former ID
DCL000824
Drug Name
GSK372475
Drug Type
Small molecular drug
Indication Attention deficit hyperactivity disorder; Severe mood disorders [ICD9: 296, 314.00, 314.01; ICD10:F30-F39, F90] Discontinued in Phase 2 [533085]
Company
GSK; NeuroSearch
Structure
Download
2D MOL

3D MOL
Formula
C15H19Cl2NO
Canonical SMILES
COCC1C2CCC(N2)CC1C3=CC(=C(C=C3)Cl)Cl
InChI
1S/C15H19Cl2NO/c1-19-8-12-11(7-10-3-5-15(12)18-10)9-2-4-13(16)14(17)6-9/h2,4,6,10-12,15,18H,3,5,7-8H2,1H3/t10-,11+,12+,15+/m0/s1
InChIKey
FPTPUYCHSWIWIB-FUTJPDQTSA-N
PubChem Compound ID
11408320
PubChem Substance ID
42487457, 53776739, 53857726, 75769703, 134339295, 134339352, 137009519, 224078872, 228731770, 244385659
Target and Pathway
Target(s) Dopamine reuptake Target Info Inhibitor [536580]
Sodium-dependent noradrenaline transporter Target Info Inhibitor [536580]
Sodium-dependent serotonin transporter Target Info Inhibitor [536580]
KEGG Pathway Serotonergic synapse
NetPath Pathway TCR Signaling Pathway
PANTHER Pathway Adrenaline and noradrenaline biosynthesisP04373:5HT1 type receptor mediated signaling pathway
5HT2 type receptor mediated signaling pathway
5HT3 type receptor mediated signaling pathway
5HT4 type receptor mediated signaling pathway
Reactome Na+/Cl- dependent neurotransmitter transporters
WikiPathways Monoamine Transport
NRF2 pathway
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compoundsWP727:Monoamine Transport
SIDS Susceptibility Pathways
Synaptic Vesicle Pathway
Serotonin Transporter Activity
References
Ref 533085Pilot Phase II study of mazindol in children with attention deficit/hyperactivity disorder. Drug Des Devel Ther. 2014 Dec 1;8:2321-32.
Ref 536580Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. Epub 2008 Jan 2.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.